Mary Schall 319-356-3516
Participants in this study have been diagnosed with Mantle Cell Lymphoma (MCL), which has been previously treated and the disease has returned. The purpose of the study is to assess the effects (both good and bad) of Ibrutinib in MCL and whether the MCL responds to treatment. The Study treatment is a maximum of 3 years, depending on how well the participant responds to treatment.
Please help us improve your experience on our website by completing a brief survey
Yes, I'll give feedback No, Thanks
Your browser does not support iframes.